TG Therapeutics (NASDAQ:TGTX) Stock Price Down 6.3%

Share on StockTwits

TG Therapeutics Inc (NASDAQ:TGTX)’s share price was down 6.3% during trading on Thursday . The stock traded as low as $7.63 and last traded at $7.68, approximately 1,758,215 shares were traded during mid-day trading. An increase of 8% from the average daily volume of 1,624,737 shares. The stock had previously closed at $8.20.

A number of analysts have weighed in on TGTX shares. ValuEngine lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, October 21st. B. Riley started coverage on TG Therapeutics in a research report on Wednesday, November 27th. They set a “buy” rating and a $12.00 target price for the company. Zacks Investment Research lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of TG Therapeutics in a report on Tuesday, November 12th. Finally, BidaskClub raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $12.95.

The company has a debt-to-equity ratio of 2.77, a quick ratio of 1.00 and a current ratio of 1.00. The company’s 50 day moving average price is $7.22 and its two-hundred day moving average price is $6.94.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.33). The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative return on equity of 2,411.79% and a negative net margin of 123,130.93%. On average, sell-side analysts expect that TG Therapeutics Inc will post -1.96 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of TGTX. Millennium Management LLC grew its position in shares of TG Therapeutics by 6,258.4% during the 3rd quarter. Millennium Management LLC now owns 7,521,910 shares of the biopharmaceutical company’s stock worth $42,235,000 after buying an additional 7,403,611 shares in the last quarter. BlackRock Inc. increased its stake in shares of TG Therapeutics by 19.5% during the second quarter. BlackRock Inc. now owns 5,304,463 shares of the biopharmaceutical company’s stock valued at $45,883,000 after buying an additional 866,572 shares during the period. Vanguard Group Inc. increased its stake in shares of TG Therapeutics by 19.7% during the second quarter. Vanguard Group Inc. now owns 4,041,122 shares of the biopharmaceutical company’s stock valued at $34,955,000 after buying an additional 665,380 shares during the period. Sofinnova Investments Inc. increased its stake in shares of TG Therapeutics by 258.5% during the second quarter. Sofinnova Investments Inc. now owns 1,261,384 shares of the biopharmaceutical company’s stock valued at $10,911,000 after buying an additional 909,573 shares during the period. Finally, Camber Capital Management LP bought a new stake in shares of TG Therapeutics in the second quarter valued at about $8,650,000. 48.63% of the stock is owned by institutional investors and hedge funds.

About TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Recommended Story: Monthly Dividend Stocks Can Provide Solid Income

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SONY FINL HOLDI/ADR  Getting Somewhat Favorable News Coverage, InfoTrie Reports
SONY FINL HOLDI/ADR Getting Somewhat Favorable News Coverage, InfoTrie Reports
Infinera Corp.  Given Average Recommendation of “Hold” by Brokerages
Infinera Corp. Given Average Recommendation of “Hold” by Brokerages
ValuEngine Lowers Fauquier Bankshares  to Sell
ValuEngine Lowers Fauquier Bankshares to Sell
DASAN Zhone Solutions  Lifted to Buy at ValuEngine
DASAN Zhone Solutions Lifted to Buy at ValuEngine
ValuEngine Downgrades CVS Health  to Strong Sell
ValuEngine Downgrades CVS Health to Strong Sell
Copa  Raised to “Sell” at ValuEngine
Copa Raised to “Sell” at ValuEngine


 
© 2006-2020 Zolmax.